GHRP-2 vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), built from a modified GRF(1-29) sequence with four amino acid swaps plus a Drug Affinity Complex (DAC) that lets it latch onto your own albumin after injection. That albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and IGF-1 up for over a week. It is not FDA approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | GHRP-2 | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like GHRP-6, GHRP-2 is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Binding that receptor in the pituitary and hypothalamus drives a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite, though it still acts on the ghrelin system so it is not free of off-target hormonal effects. Because it works upstream of the pituitary rather than replacing GH directly, the GH release it causes is still subject to the body's own feedback brakes such as somatostatin. | GHRH is the natural signal your hypothalamus sends to the pituitary to release growth hormone in pulses. CJC-1295 binds and activates the same GHRH receptor on the pituitary, prompting it to make and release more of its own growth hormone, which then raises IGF-1 from the liver. The four amino acid substitutions make it resist breakdown by the enzyme DPP-IV, and the DAC linker covalently bonds it to circulating albumin so it is not cleared quickly. Because it amplifies the body's own pulsatile signaling rather than injecting growth hormone directly, the effect is a sustained elevation rather than a single spike. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks typical |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-2 has genuine human data behind its diagnostic role. In Japan it reached phase II trials and was approved as pralmorelin (intravenous) to test for growth hormone deficiency, including in children with short stature, making it the only GH secretagogue in this class with any regulatory approval. A published human pharmacology study detected unchanged GHRP-2 and its metabolite AA-3 in the urine of ten male volunteers given the drug intravenously, work driven largely by anti-doping testing because GHRP-2 is banned in sport. What it does NOT have is solid controlled-trial evidence for the body-composition, anti-aging, or recovery uses it is marketed for online. So the honest picture is a real, approved diagnostic tool in one country, with everything beyond that being off-label or unproven research use. | The core human evidence is a single early-phase study, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy adults. A single subcutaneous dose raised GH roughly 2 to 10 fold and IGF-1 about 1.5 to 3 fold, with GH staying up for 6 days or more and IGF-1 elevated for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days. The estimated half-life was about 5.8 to 8.1 days and no serious adverse reactions were reported in that short trial. Beyond that, the data is mostly animal work, such as a study showing once-daily CJC-1295 normalized growth in GHRH knockout mice. Importantly, clinical development by the original sponsor (ConjuChem) was stopped, and a related long-acting analog program saw a Phase II lipodystrophy study halted after a participant death, although the attending physician attributed that death to pre-existing coronary disease rather than the drug. So the honest read is: short-term pharmacology in humans is documented, but there are no long-term safety or efficacy trials, no approval, and real questions about chronically elevating IGF-1. |
Frequently Asked Questions: GHRP-2 vs CJC-1295 DAC
What is the difference between GHRP-2 and CJC-1295 DAC?
GHRP-2 is a growth hormone peptide that ghrp-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of ghrp-6. it prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in japan as a diagnostic agent for growth hormone deficiency. outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound. CJC-1295 DAC is a growth hormone peptide that cjc-1295 dac is a synthetic, long-acting analog of growth hormone-releasing hormone (ghrh), built from a modified grf(1-29) sequence with four amino acid swaps plus a drug affinity complex (dac) that lets it latch onto your own albumin after injection. that albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and igf-1 up for over a week. it is not fda approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-2 or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. GHRP-2 is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-2 and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-2 and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.